The CSL Limited (ASX: CSL) share price will be on watch on Thursday after a promising announcement out of the biotherapeutics company.

What did CSL announce?

Hot on the heels of its decision to acquire clinical-stage biotechnology company Vitaeris earlier this month, this morning the company announced plans to make another acquisition.

CSL has agreed to acquire the exclusive global license rights to commercialise an adenoassociated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia from Nasdaq-listed gene therapy company, uniQure .

According to the release, the AMT-061 program, which is currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with haemophilia B.

Management explained that one dose of AMT-061 has shown to increase Factor IX (FIX) plasma levels to a degree that reduces or eliminates the tendency for bleeding for many years. FIX is the blood clotting protein lacking in people with haemophilia B.

This means that should AMT-061’s trials be successful, appropriate candidate haemophilia B patients will be able to have a one-time treatment to restore FIX activity to functional levels capable of eliminating the need for frequent and ongoing replacement therapies.

CSL’s CEO and Managing Director, Paul Perreault, commented: “Our vision for haemophilia B patients is to offer transformational treatment paradigms that help free them from the lifelong burden of this disease. With more than three decades of providing lifesaving innovations for the global bleeding disorders community, we are well positioned to maximise the potential benefit of this therapy.”

What is CSL paying for AMT-061?

Under the agreement with the gene therapy company, CSL will have the exclusive global right to commercialise AMT-061.

It will pay uniQure an upfront cash payment of US$450 million, followed by regulatory and commercial sales milestone payments and royalties.

In addition, uniQure will complete the Phase 3 trial and scale up manufacture for early commercial supply under an agreed plan with CSL. The transaction remains subject to customary regulatory clearances before closing.

Mr. Perreault concluded: “Upon approval, we believe this next-generation therapy would be highly complementary to our existing haemophilia B product portfolio. We hope that it provides patients with an alternate best-in-class treatment option, building on our legacy of delivering lifesaving innovations in hematology.”

More reading

• Why I would buy these outstanding ASX 50 shares right now
• Give your portfolio a boost with these ASX blue chip shares
• Australian businesses are running out of cash
• 3 ASX shares I’d buy if the market crashes again
• Consider these 3 quality ASX healthcare shares to buy now

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post CSL share price on watch after US$450 million acquisition news appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2CxCIyo

There aren’t many ASX shares on the market like Afterpay Ltd (ASX: APT).

The Afterpay share price has nearly doubled in value this year while the S&P/ASX 200 Index (ASX: XJO) has slumped 10.8% lower.

While many investors think the ship has sailed on the buy now, pay later leader, given its current $59.38 per share valuation, could either of these candidates be ‘the next Afterpay’?

An Afterpay Competitor

Let’s start with an obvious candidate and one of Afterpay’s top rivals: Openpay Group Ltd (ASX: OPY).

Openpay is another buy now, pay later provider that differentiates itself based on its repayment schedule flexibility. Unlike Afterpay’s fairly rigid 8-week schedule, Openpay’s repayment period can stretch as long as 18 months.

The ASX buy now, pay later share listed in December 2019 and has traded around its first closing price of $1.33 for most of the time since then.

However, the last month or so has been a different story for Openpay. From the beginning of June, the Openpay share price began surging and is now trading at $2.48 per share with a market capitalisation of $267.5 million.

The buy now, pay later sector is competitive and I think we’ll see more consolidation in the months and years ahead. While Openpay may not be the next Afterpay, the company could still attract the interest of buyers on the acquisition trail.

Of course, betting on acquisitions is a purely speculative game. If Openpay can execute its expansion plans, then it may be able to continue climbing as a top ASX growth share in 2020.

An ASX Biotech share

Of course, it’s not just competitors that could be the ‘next Afterpay’ in terms of share price growth. I think the biotechnology sector could harbour some hidden gems in the current market.

In particular, Pro Medicus Limited (ASX: PME) has caught my eye right now. The Pro Medicus share price climbed 1.5% higher yesterday and is up 23.3% for the year.

The Aussie biotech company is a leading imaging technology company specialising in radiology IT services. It boasts a current market capitalisation of $2.9 billion.

In the short-term, I think demand for Pro Medicus’ services will be high given the backlog of medical work arising from COVID-19 lockdowns. Thinking longer-term, there’s a huge addressable market for Pro Medicus due to increasing use of imagery and medical technology overall.

Foolish takeaway

These are just a couple of the ASX shares I’ve got my eye on right now. I think both Openpay and Pro Medicus could have strong growth trajectories going forward.

There aren’t many companies like Afterpay out there, and it can take both savvy investing and a bit of luck to find them.

More reading

• Why Xero and these ASX tech shares just hit record highs
• 3 high quality ASX shares I would buy if there were another market crash
• 3 star ASX shares to buy for the rest of 2020
• 5 things to watch on the ASX 200 on Thursday
• Why the risks of a market correction for the ASX 200 is rising

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Could one of these ASX shares be ‘the next Afterpay’? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3dvB7G8

One of the most important large cap equity indices is the S&P/ASX 50 index. It represents 50 of the largest and most liquid shares listed on the ASX by market capitalisation.

Among these 50 companies are a number that I believe are outstanding long term investment options. Three ASX 50 shares that I would buy today are listed below:

BHP Group Ltd (ASX: BHP)

I think BHP is an ASX 50 share to consider buying. I believe the mining giant is the most outstanding option in the resources sector. This is due to the diversity of its world class operations and their extremely low costs. The latter means that BHP is able to fully benefit from favourable prices of many commodities it produces such as iron ore. I believe this leaves it well-placed to generate strong free cash flows again this year and in FY 2021. And given how strong its balance sheet is, this is likely to mean generous dividends being paid to shareholders.

CSL Limited (ASX: CSL)

A second ASX 50 share to look at is biotherapeutics giant CSL. I think CSL is the highest quality option on the index and well-placed to deliver solid earnings growth over the next decade. This is due to its leading and lucrative therapies, growing plasma collection network, and its impressive research and development (R&D) pipeline. The latter contains a number of therapies which have the potential to generate billions of dollars in sales over the next decade if their trials are successful.

Goodman Group (ASX: GMG)

A final ASX 50 share to consider buying is Goodman Group. It owns, develops, and manages industrial real estate across several countries. I’m a big fan of the company because of its high quality portfolio and exposure to markets with very positive long term outlooks. The latter includes its exposure to ecommerce through relationships with giant such as Amazon, DHL, and Walmart. I expect these assets to be in demand for a long time to come.

More reading

• CSL share price on watch after US$450 million acquisition news
• Give your portfolio a boost with these ASX blue chip shares
• Australian businesses are running out of cash
• 3 ASX shares I’d buy if the market crashes again
• This top fund manager believes dividend yields are going to 0%. Where should you invest?

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why I would buy these outstanding ASX 50 shares right now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/319cooG

Are you looking for better interest rates than those on offer with savings accounts or term deposits? Good news! Despite the pandemic, the Australian share market is still home to a good number of shares offering generous dividends.

Three ASX dividend shares which I think are top options right now are listed below:

BWP Trust (ASX: BWP)

The first dividend share to consider buying is this real estate investment trust. It leases the majority of its portfolio to hardware giant Bunnings, which I feel is a fantastic tenant to have. The benefits of this were demonstrated yesterday when BWP revealed its estimated final distribution for FY 2020. The company intends to declare a 9.27 cents per unit distribution, which will bring its full year distribution to a total of 18.29 cents per unit. Based on its last close price, this equates to a 4.65% distribution yield.

Commonwealth Bank of Australia (ASX: CBA)

I think the pullback in the Commonwealth Bank share price this year has brought it down to an attractive level for a patient investment. Especially as I’m optimistic that the worst is now behind the banks after the Royal Commission, bushfires, and pandemic. This could even mean that a return to growth isn’t too far away for the bank. For now, though, I expect Commonwealth Bank to cut its dividend down to approximately $3.70 per share in FY 2021. This equates to a fully franked forward 5.3% dividend yield.

Sydney Airport Holdings Pty Ltd (ASX: SYD)

Investors that are not in immediate need for dividends might want to consider Sydney Airport. I’m not overly convinced the airport operator will pay a final dividend this year, or if it does it will be significantly reduced. However, as long as Australia avoids a second wave of coronavirus, I believe the domestic tourism market will have recovered enough for Sydney Airport to pay a decent 29 cents per share dividend in FY 2021. If this proves accurate, it will mean a 5% dividend yield next year.

More reading

• Australian businesses are running out of cash
• This top fund manager believes dividend yields are going to 0%. Where should you invest?
• The CBA share price is down 13% this year. Is it a cheap buy?
• My 3 high-yield ASX dividend shares to buy now
• Coronavirus second wave potential could drive investment portfolio changes

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why I would buy CBA and these ASX dividend shares appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/380n0aY

Although the All Ordinaries (ASX: XAO) index is still some way off its highs for the year, this isn’t the case for all constituents of the index.

In fact, three popular ASX tech shares have just hit record highs. Here’s why they are on a high right now:

The Afterpay Ltd (ASX: APT) share price stormed to a new record high of $62.33 on Wednesday. This latest gain was driven by the payment company’s update on its UK business. That update reveals that Afterpay’s UK-based Clearpay business has reached 1 million customers after 12 months in the country. Also supporting its shares this year has been stellar customer and sales growth in the United States and the arrival of Tencent Holdings on its share registry. The latter could be the key to a future launch into the Asia market.

The Pushpay Holdings Ltd (ASX: PPH) share price continued its positive run and hit a new record high of $8.97 yesterday. Investors have been fighting to buy the donor management platform provider’s shares following the release of a very strong full year result in May and a guidance upgrade this month. The latter came just six weeks after first issuing its guidance. Pushpay now expects EBITDA of US$50 million to US$54 million in FY 2021. This compares to its previous guidance of US$48 million to US$53 million and will be double FY 2020’s operating earnings.

The Xero Limited (ASX: XRO) share price reached a record high of $91.94 on Wednesday. Investors have been buying the business and accounting software provider’s shares this year thanks to its strong FY 2020 result. During the 12 months, Xero delivered a 30% increase in operating revenue to NZ$718.2 million and a 29% jump in annualised monthly recurring revenue to NZ$820.6 million. This was driven by increases in both its average revenue per user and total subscriber numbers. The latter rose 26% to 2.285 million thanks to the addition of 467,000 net subscribers during the year. Judging by its strong share price form since then, investors appear confident there will be more of the same over the coming years. And I would have to agree.

More reading

• 3 high quality ASX shares I would buy if there were another market crash
• 3 star ASX shares to buy for the rest of 2020
• ASX 200 finishes higher, Afterpay hits new record
• 3 ASX payments shares that could double your money
• Australian businesses are running out of cash

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of PUSHPAY FPO NZX and Xero. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended PUSHPAY FPO NZX. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Xero and these ASX tech shares just hit record highs appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2Z3lPmQ